MMM. Jules. Mattes

M. Jules. Mattes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M. Jules. Mattes has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Induction of Apoptosis by Cross-Linking Antibodies Bound to Human B-Lymphoma Cells: Expression of Annexin V Binding Sites on the Antibody Cap

    by M. Jules Mattes, Rosana B. Michel, David M. Goldenberg, Robert M. Sharkey

    There are many reports that cross-linking antibodies (Abs) bound to the surface of B-lymphoma cells can induce apoptosis and/or cell death, especially with anti-CD20 Abs. This study was intended to extend our understanding of these effects. To determine if CD20 is a unique target in this respect, or whether Abs to other antigens would have similar effects, six Abs were tested, with and without cross-linking with a secondary Ab, on three target cell lines. We utilized assays that distinguish between apoptotic, dead, and viable cells. Two assays were used: Annexin V plus propidium iodide, and JC-1 plus SYTOX green (Molecular Probes, Eugene, OR). Most of the Abs tested induced a low level of apoptosis and cell death in Ramos cells, but not in the other two cell lines (Raji and RL). In general, the level of toxicity was correlated with the level of antigen expression, with Abs to high-density antigens having the strongest effects. However, since the majority of Ramos cells continued to multiply, it is questionable whether toxicity at this level can provide a significant clinical benefit. Unexpectedly, there was also a population of cells that stained weakly with Annexin V. These cells were distinct from classical apoptotic cells, and appeared to belong to the viable cell population. In these cells, Annexin V stained the region of the Ab cap, in contrast to the ringed staining of classical apoptotic cells. 1) Low-level induction of apoptosis was not unique for anti-CD20 Abs, but occurred similarly with other Abs, and 2) results of Annexin V staining experiments may need to be reevaluated. Further studies are required to explain why Annexin V binding sites are exposed in the region of an Ab cap.


  • Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons

    by M. Jules Mattes, David M. Goldenberg

    Purpose Low-energy electrons (10–50 keV) can be effective and specific cytotoxic agents when delivered to the cell surface by antibodies, because their path length in tissue is comparable to a cell diameter. In this study, we have begun to evaluate the therapeutic potential of antibodies (Abs) conjugated to 111In against carcinoma xenografts in nude mice. Methods Abs to EGFr or HER-2 were labeled with 111In to a high specific activity of approximately 1.48 GBq/mg (40 mCi/mg). They were injected into nude mice 5–6 days after inoculation of human carcinoma cells, either A431 or SK-OV-3, and tumor growth was monitored. In preliminary in vitro experiments, we calculated the cumulative decays per cell, estimated the centigray dose delivered to the nucleus, and related this to the fraction surviving. Results Abs to both antigens provided significant protection in nude mouse xenograft models (p values ranging from 111In, can be effective therapeutic agents against microscopic s.c. tumors. This strategy should be considered for clinical applications.


  • The mechanism of killing of B-lymphoma cells by111In-conjugated antibodies

    by M. Jules Mattes

    Purpose: To determine the mode of killing of B-lymphoma cell lines by 111In-conjugated antibodies (Ab). Materials and methods: Cells were treated with a range of radiolabeled Ab concentrations to produce a level of killing from 80 – 99.9%, as determined by a long-term proliferation assay. On days 1, 2, 3 and 4, apoptosis was evaluated in individual cells by two assays: (i) Mitochondrial function by JC-1 staining; and (ii) presence of cleaved PARP (poly-ADP-ribose-polymerase) by immunofluorescence. Five cell lines were tested, including two non-Burkitt lines, RL and FSCCL. Results: In preliminary experiments, it was realized that the standard JC-1 assay, which is widely used, does not distinguish between apoptotic and necrotic cells. The JC-1 assay becomes useful if it is combined with a stain for lysed cells, Sytox green, and then is able to distinguish between viable, apoptotic and necrotic cells. Of the 5 cell lines tested, only Ramos had a large population of apoptotic cells detected by the modified JC-1 assay, but all four of the other cell lines showed evidence of cleaved PARP, albeit to markedly different degrees. The caspase inhibitor, Z-VAD (N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone), significantly inhibited the killing of Daudi cells. Conclusions: Apoptosis was activated in at least four of the five cell lines tested, and participated in the killing of the cells. Staining for cleaved PARP was much more sensitive than the modified JC-1 assay, for most cell lines, probably because it can detect cells that have already lysed, but which died via apoptosis. In addition, the methodological issues discussed may lead to a better understanding of the role of apoptosis in tumor cell cytotoxicity.


  • Open Access

    Apoptosis assays with lymphoma cell lines: problems and pitfalls

    by M J Mattes

    Much attention has been focused on the manner in which tumour cells die after treatment with cytotoxic agents. The basic question is whether cells die via apoptosis or via direct damage from the toxic agent. Various assays have been used to make this distinction. However, we show herein that some of the widely used assays for apoptosis do not in fact distinguish between apoptosis and other forms of cell death. More specifically: (1) A sub-G1 DNA content, identified by propidium iodide staining, does not distinguish between apoptotic and necrotic cells; (2) loss of mitochondrial membrane potential does not distinguish between apoptotic and necrotic cells, unless combined with an assay for an intact cell membrane; (3) subcellular fragments that arise from dead cells or from apoptotic bodies can interfere with some assays for apoptosis such as annexin V staining, as they may be close to the size of intact cells, making it difficult to decide where to set the size threshold; (4) irradiated cells display a large increase in nonspecific Ab binding. This may be partly due to an increase in cell size, but, regardless of the cause, it can lead to a mistaken conclusion that there is an increase in a particular antigen if appropriate control reagents are not tested; and (5) experiments utilising Ab crosslinking have neglected the role of cell aggregation, which can cause multiple problems including death from mechanical stress when cells are handled. Consideration of these factors will improve our ability to determine the mode of cell death.


  • Open Access

    Characterization of antibody-containing vesicles shed from B-lymphoma cell lines: exposure of annexin V binding sites

    by Rosana B. Michel, Mones Abu-Asab, Maria Tsokos, M. Jules Mattes

    Antibodies (Abs) to CD20 or HLA-DR, after binding to the B-lymphoma cell line RL following an overnight incubation at 37°C, accumulate in the form of shed vesicles, which develop in the center of the cell clusters that are spontaneously formed by this cell line. These vesicles coalesce into fairly stable large structures, which we refer to as conglomerates of shed vesicles (CSVs). In the present study, we have extended our previous investigations into the nature of this material. Electron microscopy revealed a conglomerate of heterogeneous vesicles, which looked like pinched-off cytoplasmic projections. CSVs developed similarly either with or without Ab, demonstrating that CSV production is a spontaneous process that incorporates bound Abs if they are present. Before delivery to CSVs, the Abs capped on the cell surface. CSVs had high expression of annexin V binding sites, which are phagocytic signals that are exposed on damaged cells. For CSVs that were cell bound, which are frequently observed, the annexin V binding sites were only in the CSVs, and not on the surface of the intact cell. Although all CSVs contained both Abs and annexin V binding sites, the precise distribution of these two ligands was generally different. Annexin V binding sites were present on caps as well as on CSVs, and appear as soon as caps are formed. In cells incubated with anti-HLA-DR, CD20 was delivered to the CSVs together with HLA-DR, suggesting an association between these two molecules. CSVs prepared with anti-HLA-DR, but not CSVs prepared with anti-CD20, contained considerable numbers of nuclear fragments, identified by propidium iodide staining.


  • Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugates

    by Serengulam V. Govindan, Rosana B. Michel, Gary L. Griffiths, David M. Goldenberg, M. Jules Mattes


  • Open Access

    In vitrocytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2

    by Rosana B. Michel, Philip M. Andrews, Mary Ellen Castillo, M. Jules Mattes

    Antibodies conjugated to radionuclides emitting low-energy electrons, which include Auger electrons and some conversion electrons, were recently shown to efficiently kill cells bearing a high density of the antigen recognized. The primary purpose of this study was to determine if such killing could be obtained with anti–HER-2 antibodies conjugated to 111In, using the chelator benzyl-diethylenetriaminepentaacetic acid, or 125I. Target cells were the breast carcinoma SK-BR-3 and the ovarian carcinoma SK-OV-3.ip1. In preliminary experiments, antibody accumulation and catabolism during a 2- to 3-day incubation with antibody was investigated. The level of antibody uptake, in terms of molecules per cell, was high enough such that killing seemed feasible. With an 125I label, but not an 111In label, increasing the antibody concentration past a certain point caused a decrease in total antibody accumulation, which might be attributed to effects of antibody binding. To test for cytotoxicity, cells were incubated for 2 days with the labeled antibody, then assayed for colony-forming units with a limiting dilution assay. SK-BR-3 cells were strongly killed (∼3 logs) by antibody 21.1, and 100% kill was obtained by combining two noncompeting antibodies to HER-2 (21.1 and 4D5). SK-OV-3.ip.1 cells were more resistant to killing, but use of the two-antibody mixture produced a surviving fraction of ∼0.002. 111In-labeled antibodies to other high-density antigens, epithelial glycoprotein-1 and epithelial glycoprotein-2, also killed these target cells. In contrast, unlabeled antibodies or a nonreactive-labeled antibody produced much less cytotoxicity. The same experiment with an 131I label (a β-particle emitter) resulted in much greater levels of nonspecific cytotoxicity and essentially no specific cytotoxicity. This approach may be effective for therapy of micrometastases.


  • Open Access

    Therapy of Small Subcutaneous B-Lymphoma Xenografts with Antibodies Conjugated to Radionuclides Emitting Low-Energy Electrons

    by Rosana B. Michel, Adriane V. Rosario, Philip M. Andrews, David M. Goldenberg, M. Jules Mattes

    Purpose: Radionuclides emitting low-energy electrons (Auger and conversion electrons of <50 keV) are potentially useful for cancer therapy when conjugated to an antibody, because they can irradiate the cell to which they bind while producing relatively little irradiation of surrounding cells and tissues. We showed previously the ability of such antibody conjugates to treat micrometastatic, disseminated human B-lymphoma in a severe combined immunodeficient mouse model using an anti-CD74 antibody. In this study, we have evaluated the ability of such conjugates to treat s.c. tumors.Experimental Design: Severe combined immunodeficient mice were injected s.c. with Raji, Daudi, or RL B-lymphoma human tumor cells. Antibodies to CD74, CD20, or HLA-DR were radiolabeled with 111In or 125I and injected i.v. at various times starting at day 5, and tumor growth was monitored. Controls included the testing of unlabeled antibodies, labeled nonreactive antibodies, and a combination of the two.Results: Therapy of s.c. B-lymphoma was more difficult than therapy of tumor cells that had been injected i.v. Although large, macroscopic tumors were not effectively treated, therapy was effective on s.c. Daudi tumors on day 36 after injection of this slowly growing tumor, with an 111In anti-CD74 antibody given in two doses. An anti-CD20 antibody labeled with either 111In or 125I was able to effectively treat s.c. RL tumors when given as late as day 16 after tumor inoculation. The largest tumors that were effectively treated were macroscopic thin discs (<2 mm in diameter) growing on the mesentery.Conclusion: These results extend previous evidence that antibody conjugates with emitters of low-energy electrons can be effective therapeutic agents for micrometastatic cancer.


  • Binding parameters of antibodies: pseudo-affinity and other misconceptions

    by M. Jules. Mattes

    In order to evaluate and compare monoclonal antibodies (Abs), functional affinities are generally determined. While the equations that define affinity relate to monovalent interactions, it has been considered that the binding of Abs to multivalent antigens such as the cell surface could be described by an apparent, or functional affinity. We demonstrate here that this concept is incorrect, since the binding interactions that occur cannot be described in terms of a functional affinity, and the values that are obtained serve only to obscure the true interactions. Bivalent Ab binding must be considered to be an irreversible reaction, in most cases. A correct understanding of Ab binding will be useful in the further development of Abs for therapeutic purposes.